Terbium-161 for PSMA-targeted Radionuclide Therapy of Prostate Cancer

European Journal of Nuclear Medicine and Molecular Imaging - Germany
doi 10.1007/s00259-019-04345-0
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

225Ac-Psma-617 for PSMA-Targeted -Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2016English

Preclinical Efficacy of a PSMA-targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

[ 177 Lu]-Psma-617 Radionuclide Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer – Author's Reply

The Lancet Oncology
Oncology
2018English

Targeted Radionuclide Therapy

Journal of Labelled Compounds and Radiopharmaceuticals
Organic ChemistryNuclear MedicineRadiologyBiochemistryAnalytical ChemistryImagingSpectroscopyDrug Discovery
2007English

The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2016English

Targeted Therapy of Cancer: New Roles for Pathologists—prostate Cancer

Modern Pathology
Forensic MedicinePathology
2008English

Global Trends Survey for Targeted Radionuclide Therapy

Nippon Hoshasen Gijutsu Gakkai zasshi
Medicine
2018English

Targeted Α-Therapy of Metastatic Castration-Resistant Prostate Cancer With225Ac-Psma-617: Dosimetry Estimate and Empiric Dose Finding

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2017English

Prostate Cancer Stem Cells: Molecular Characterization for Targeted Therapy

Asian Journal of Andrology
MedicineUrology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy